White blood count as a predictor of glucose tolerance and insulin sensitivity:: the role of inflammation in the pathogenesis of type 2 diabetes

被引:0
|
作者
Fritsche, A [1 ]
Häring, H [1 ]
Stumvoll, M [1 ]
机构
[1] Univ Tubingen, Innere Med Abt 4, Med Klin, Tubingen, Germany
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objective: Chronic subclinical activation of the immune system is probably involved in the pathogenesis of type 2 diabetes. In the present study we examined whether an association exists between a non-specific inflammatory marker such as white blood count (WBC) and factors relevant to the pathogenesis of type 2 diabetes. Patients and methods: The statistical association between WBC and glucose tolerance, insulin secretion and insulin sensitivity estimated in an oral glucose tolerance test (OGTT, n = 607) or measured during an euglycemic clamp (N = 280) was determined in non-diabetic individuals. Results: WBC was positively correlated with body weight (r = 0.32, p < 0.001) and postprandial (2-hour) blood glucose during the OGTT (r=0.22, p < 0.001) independent of sex, age and percentage body fat. WBC negatively correlated with insulin sensitivity both measured by the euglycemic clamp (r = -0.23, p < 0.001) and estimated from the OGTT (r = -0.34, p < 0.001). This relationship remained significant upon adjusting for sex, age and percentage body fat. No relationship between WBC and insulin secretion independent of percentage body fat and insulin sensitivity was found (p = 0.95). Conclusion: An increase in WBC is associated with deterioration of glucose tolerance. This is mostly explained by reduced insulin sensitivity. These results are compatible with the hypothesis that chronic subclinical inflammation is involved in the pathogenesis of type 2 diabetes.
引用
收藏
页码:244 / 248
页数:5
相关论文
共 50 条
  • [31] The role of insulin secretion and resistance in the pathogenesis of type 2 diabetes in Chinese
    Jia, WP
    Xiang, KS
    Lu, JX
    Zheng, YM
    Tang, JL
    DIABETOLOGIA, 1998, 41 : A197 - A197
  • [32] Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes
    Lindsay, JR
    McKillop, AM
    Mooney, MH
    O'Harte, FPM
    Flatt, PR
    Bell, PM
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2003, 61 (03) : 167 - 173
  • [33] Evaluation of obese youth at risk for type 2 diabetes: Fasting glucose and insulin or glucose tolerance?
    Greig, Fenella
    Hyman, Sharon
    Patel, Arti
    Bowlby, Deborah
    Wallach, Elizabeth
    Rapaport, Robert
    DIABETES, 2006, 55 : A601 - A601
  • [34] Blood glucose self monitoring in insulin treated type 2 diabetes
    Schiel, R
    Müller, UA
    Rauchfuss, J
    Sprott, H
    Müller, R
    DIABETOLOGIA, 1998, 41 : A40 - A40
  • [35] A new index of insulin sensitivity obtained from the oral glucose tolerance test applicable to advanced type 2 diabetes
    Kanauchi, M
    DIABETES CARE, 2002, 25 (10) : 1891 - 1892
  • [36] Beneficial effects of repaglinide on glucose tolerance and insulin sensitivity in African-Americans with type 2 diabetes mellitus.
    Burgun, SJ
    Gaillard, TR
    Osei, K
    JOURNAL OF INVESTIGATIVE MEDICINE, 2000, 48 (05) : 264A - 264A
  • [37] Role for the Carotid Chemoreceptors in Glucose Tolerance in Human Type 2 Diabetes
    Pipkins, Aubrey
    Lis, Eric
    Ott, Elizabeth
    Harper, Jennifer
    Manrique-Acevedo, Camila
    Limberg, Jacqueline
    PHYSIOLOGY, 2024, 39
  • [38] ROLE OF GLYCEMIA IN INSULIN SENSITIVITY IN ADOLESCENTS WITH TYPE 1 AND TYPE 2 DIABETES
    Alam, S.
    West, A.
    Downey, M.
    Forster-Harwood, J.
    Reusch, J. E.
    Nadeau, K. J.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2012, 60 (01) : 223 - 223
  • [39] Brain control of blood glucose levels: implications for the pathogenesis of type 2 diabetes
    Kimberly M. Alonge
    David A. D’Alessio
    Michael W. Schwartz
    Diabetologia, 2021, 64 : 5 - 14
  • [40] The role of blood glucose monitoring in non-insulin treated type 2 diabetes: What is the evidence?
    Benhalima, Katrien
    Mathieu, Chantal
    PRIMARY CARE DIABETES, 2012, 6 (03) : 179 - 185